CMP Therapeutics Ltd Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Welwyn Garden City United Kingdom (2004)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2006
NCT00443495
First Marketed Drug
2004
sodium polystyrene sulfonate (kayexalate)
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

CMP Development, LLC | CMP DEV LLC | CMP PHARMA INC | CMP Therapeutics Ltd

Active Ingredients

Marketed Drugs (11)

amantadine (symmetrel) (2002)

amlodipine (norvasc) (2022)

atorvastatin (lipitor) (2023)

isoniazid (nydrazid) (1983)

potassium phosphate (Tis-U-Sol) (2019)

sildenafil (viagra) (2023)

sodium polystyrene sulfonate (kayexalate) (1982)

spironolactone (aldactone) (2017)

tadalafil (cialis) (2022)

triamcinolone (kenalog) (1995)

urea (1985)

Drugs in Phase 4 Trials (1)

spironolactone (aldactone) (2 trials)

Drugs in Phase 2 Trials (1)

chitin (1 trial)

Drugs in Phase 1 Trials (1)

digoxin (lanoxin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3